Day One Biopharmaceuticals (DAWN) Insider Trading & Ownership $6.28 +0.02 (+0.24%) As of 01:19 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Day One Biopharmaceuticals (NASDAQ:DAWN) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage6.20%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)6Amount OfInsider Selling(Last 12 Months)$2.31 M Get DAWN Insider Trade Alerts Want to know when executives and insiders are buying or selling Day One Biopharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address DAWN Insider Buying and Selling by Quarter Day One Biopharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails5/16/2025Adam DubowGeneral CounselSell4,552$6.26$28,495.52 5/16/2025Charles N York IICFOSell4,282$6.26$26,805.32 5/16/2025Jeremy BenderCEOSell13,964$6.26$87,414.64 5/16/2025Lauren MerendinoInsiderSell3,927$6.26$24,583.02 2/18/2025Adam DubowGeneral CounselSell4,646$11.96$55,566.16 2/18/2025Charles N York IICFOSell4,370$11.96$52,265.20 2/18/2025Jeremy BenderCEOSell12,048$11.96$144,094.08 12/10/2024Samuel C BlackmanInsiderSell30,000$13.31$399,300.00 11/11/2024Samuel C BlackmanInsiderSell10,000$16.10$161,000.00 11/7/2024Samuel C BlackmanInsiderSell11,245$16.03$180,257.35 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 10/31/2024Samuel C BlackmanInsiderSell500$16.02$8,010.00 9/10/2024Samuel C BlackmanInsiderSell30,000$14.22$426,600.00 8/16/2024Adam DubowGeneral CounselSell3,202$14.00$44,828.00 8/16/2024Charles N York IICFOSell2,633$14.00$36,862.00 8/16/2024Jeremy BenderCEOSell10,681$14.00$149,534.00 8/16/2024Samuel C BlackmanInsiderSell2,232$14.00$31,248.00 7/16/2024Samuel C BlackmanInsiderSell20,000$16.01$320,200.00 6/21/2024Saira RamasastryDirectorSell10,000$13.19$131,900.00 (Data available from 1/1/2013 forward) DAWN Insider Trading Activity - Frequently Asked Questions Who is on Day One Biopharmaceuticals's Insider Roster? The list of insiders at Day One Biopharmaceuticals includes Adam Dubow, Ai Day1 Llc, Charles N York II, Jeremy Bender, Julie Papanek Grant, Lauren Merendino, Michael Gladstone, Papanek Julie Grant, Saira Ramasastry, Samuel C Blackman, and Xi L.P. Canaan. Learn more on insiders at DAWN. What percentage of Day One Biopharmaceuticals stock is owned by insiders? 6.20% of Day One Biopharmaceuticals stock is owned by insiders. Learn more on DAWN's insider holdings. Which Day One Biopharmaceuticals insiders have been buying company stock? The following insider purchased DAWN shares in the last 24 months: Ai Day1 Llc ($13,867,054.00). How much insider buying is happening at Day One Biopharmaceuticals? Insiders have purchased a total of 1,153,630 DAWN shares in the last 24 months for a total of $13,867,054.00 bought. Which Day One Biopharmaceuticals insiders have been selling company stock? The following insiders have sold DAWN shares in the last 24 months: Adam Dubow ($292,747.39), Charles N York II ($1,301,303.75), Jeremy Bender ($2,117,525.48), Lauren Merendino ($24,583.02), Saira Ramasastry ($131,900.00), and Samuel C Blackman ($2,440,913.90). How much insider selling is happening at Day One Biopharmaceuticals? Insiders have sold a total of 415,497 Day One Biopharmaceuticals shares in the last 24 months for a total of $6,308,973.54 sold. Day One Biopharmaceuticals Key ExecutivesDr. Jeremy Bender M.B.A. (Age 53)Ph.D., CEO, President & Director Compensation: $900kDr. Samuel C. Blackman M.D. (Age 55)Ph.D., Co-Founder and Head of R&D Compensation: $651kMr. Charles N. York II (Age 47)COO, CFO & Secretary Compensation: $715k2 recent tradesDr. Mike Preigh Ph.D.Chief of Technology OperationsMr. Adam Dubow (Age 57)General Counsel 2 recent tradesMs. Jaa RobersonChief People OfficerDr. Davy Chiodin Ph.D.Pharm.D., Chief Development OfficerMs. Lauren Merendino M.B.A. (Age 48)Chief Commercial Officer 1 recent tradesDr. Elly Barry M.D.Chief Medical Officer More Insider Trading Tools from MarketBeat Related Companies MoonLake Immunotherapeutics Insider Buying Immunovant Insider Buying ImmunityBio Insider Buying Xenon Pharmaceuticals Insider Buying Amneal Pharmaceuticals Insider Buying Organon & Co. Insider Buying Mirum Pharmaceuticals Insider Buying Apellis Pharmaceuticals Insider Buying Arrowhead Pharmaceuticals Insider Buying Vericel Insider Buying Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Turbulence for Joby Shares: What's Behind the Recent Dip?UnitedHealth Insiders Double Down: Is UNH Stock a Value Play?Sprouts Stock: Insider Sales, But Strong Bullish Signals5 Hot Small-Cap Insiders Bought at the Peak of Tariff FearsThe Top-Ranked Insider Buys From April by Market Cap This page (NASDAQ:DAWN) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Day One Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Day One Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
